A New Dopamine and Norepinephrine Reuptake Inhibitor for Excessive Sleepiness
The Carlat Psychiatry Report, Volume 17, Number 6&7, June 2019
Talia Puzantian, PharmD, BCPP
Chris Aiken, MD.
Drs. Puzantian and Aiken have disclosed that they have no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Solriamfetol (Sunosi) was just approved for excessive daytime sleepiness in narcolepsy and sleep apnea, but it may have important psychiatric effects as well.